A Modified Peptide Redirects the Immune System to Prevent an MS-Like Disease in Mice

Researchers synthesized an altered peptide ligand (APL) of PLP 139-151 with a single substitution at the primary T cell receptor contact point. They tested whether the APL could prevent EAE in mice when co-administered with the disease-inducing native peptide. They characterized the T cell response by measuring cytokine profiles (Th1 vs Th2) and performed adoptive transfer experiments where APL-generated T cells were transferred to naive mice to test for protective effects.

This study demonstrated a powerful concept: you can take the very peptide that triggers an autoimmune attack and subtly modify it to redirect the immune system toward a protective response instead. This 'immune deviation' approach became a foundational strategy in peptide immunotherapy research for multiple sclerosis and other autoimmune diseases, showing that precision at the single amino acid level can flip the immune switch from attack to tolerance.

This 1995 study was a landmark in peptide immunotherapy, establishing that altered peptide ligands could induce 'immune deviation' — shifting destructive immune responses toward protective ones. While subsequent human trials of APLs for MS had mixed results (some causing disease flares), the concept of using modified peptides to retrain the immune system remains a cornerstone of autoimmune therapy research and has influenced vaccine design and tolerance induction strategies.

This is an animal model study using EAE in mice, which does not perfectly replicate human multiple sclerosis. The immune system in mice is simpler than in humans, and APL approaches that work in mice have had mixed results in human trials. The study does not address long-term durability of protection or potential safety risks of immune deviation.